- Home
- KOP vs AUTL Comparison
KOP vs AUTL Comparison
Compare KOP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOP | AUTL |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 433.8M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KOP | AUTL |
|---|---|---|
| Price | $34.42 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $52.50 | $8.33 |
| AVG Volume (30 Days) | 130.9K | ★ 1.6M |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,923,600,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $672.42 |
| Revenue Next Year | $1.94 | $84.48 |
| P/E Ratio | $43.64 | ★ N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $22.99 | $1.11 |
| 52 Week High | $35.61 | $2.70 |
Technical Indicators
Market Signals| Indicator | KOP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 82.58 | 44.67 |
| Support Level | $28.99 | $1.38 |
| Resistance Level | $31.88 | $1.48 |
| Average True Range (ATR) | 0.90 | 0.07 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 92.33 | 55.88 |
Price Performance
Historical ComparisonAbout KOP Koppers Holdings Inc.
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.